EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ 1 R Agonists/HDAC Inhibitor Dual‐Acting Compounds

Antonino N Fallica iD, Carla Barbaraci iD, M Carmen Ruiz-Cantero iD, Arianna Scarlatti iD, Alessandro Coco, Giorgia Giordano, Alfonsina La Mantia, Orazio Prezzavento, Antonio Di Stefano iD, Ivana Cacciatore iD, Giacomo Siano iD, Antonino Cattaneo und 5 weitere

ChemMedChem · 13.03.2026 · 21 (5)

DOI: 10.1002/cmdc.202500922 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 13.03.2026. Verfasst von Antonino N Fallica und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug and Health Sciences, University of Catania, Catania, Italy. Hauptthemen laut MEDLINE: Receptors, sigma, Histone Deacetylase Inhibitors, tau Proteins, Neuroprotective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative diseases, like Alzheimer's disease (AD), are characterized by the accumulation of tau aggregates, leading to neuronal dysfunction and cognitive decline. This study explores the development of dual‐acting compounds combining sigma‐1 receptor ( σ 1 R) agonists and histone deacetylase inhibitors (HDACi) to target these pathological mechanisms. Compounds 2d and 3a demonstrated high affinity for σ 1 R and significantly reduced tau aggregation and phosphorylation in vitro, notably at the AT8 epitope. These dual‐acting compounds destabilized tau aggregates, increased tau solubility, and showed favorable pharmacokinetic properties, with compound 2d exhibiting enhanced chemical stability and longer half‐life than 3a . In vivo, both compounds confirmed a σ 1 R agonist profile by reversing the effect of the σ 1 R antagonist BD‐1063. This dual‐action approach, acting on both HDAC and σ 1 R pathways, holds significant potential for treating tauopathies. While further optimization and clinical evaluation are needed, these findings provide a strong foundation for the continued development of multimodal therapies for neurodegenerative diseases treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, sigmaHistone Deacetylase Inhibitorstau ProteinsNeuroprotective AgentsHumansAnimalsSigma-1 ReceptorStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugHistone DeacetylasesRats

Stichwörter der Autor:innen

σ1R agonistsHDAC inhibitorsdual‐acting compoundsneurodegenerative diseasesneuroprotectionphenylbutyric acidsigma receptors (σRs)tau proteinvalproic acid

Substanzen

Receptors, sigmaHistone Deacetylase Inhibitorstau ProteinsSigma-1 ReceptorNeuroprotective AgentsHistone Deacetylases

Autor:innen und Institutionen

  • Department of Drug and Health Sciences, University of Catania, Catania, Italy.
  • Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
  • Laboratori de Química Farmacèutica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.
  • Laboratorio di Biologia Bio@SNS, Scuola Normale Superiore di Pisa, Pisa, Italy.
  • Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Chieti Scalo, Italy.

ORCID-Profile: Antonino N Fallica, Carla Barbaraci, M Carmen Ruiz-Cantero, Arianna Scarlatti, Antonio Di Stefano, Ivana Cacciatore, Giacomo Siano, Cristina Di Primio, Emanuele Amata, Agostino Marrazzo

Förderung

  • Ministero dell'Università e della Ricerca

Zitieren

APA

Fallica, A. N., Barbaraci, C., Ruiz-Cantero, M. C., Scarlatti, A., Coco, A., Giordano, G., La Mantia, A., Prezzavento, O., Di Stefano, A., Cacciatore, I., Siano, G., Cattaneo, A., Pasquinucci, L., Cobos, E. J., Di Primio, C., Amata, E., & Marrazzo, A. (2026). Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ 1 R Agonists/HDAC Inhibitor Dual‐Acting Compounds. ChemMedChem, 21(5). https://doi.org/10.1002/cmdc.202500922

Vancouver

Fallica AN, Barbaraci C, Ruiz-Cantero MC, Scarlatti A, Coco A, Giordano G, et al. Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ 1 R Agonists/HDAC Inhibitor Dual‐Acting Compounds. ChemMedChem. 2026;21(5). doi:10.1002/cmdc.202500922

BibTeX
@article{Fallica2026,
  author = {Fallica, Antonino N and Barbaraci, Carla and Ruiz-Cantero, M Carmen and Scarlatti, Arianna and Coco, Alessandro and Giordano, Giorgia and La Mantia, Alfonsina and Prezzavento, Orazio and Di Stefano, Antonio and Cacciatore, Ivana and Siano, Giacomo and Cattaneo, Antonino and Pasquinucci, Lorella and Cobos, Enrique J and Di Primio, Cristina and Amata, Emanuele and Marrazzo, Agostino},
  title = {Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ 1 R Agonists/HDAC Inhibitor Dual‐Acting Compounds},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {5},
  doi = {10.1002/cmdc.202500922}
}
Kostenlos starten →